Literature DB >> 33555988

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.

Yuzhong Li1, Yanwei Bi1, Hongjian Xiao1, Yueting Yao1, Xiaojuan Liu1, Zhengrong Hu1, Jinmei Duan1, Yaoyun Yang1, Zhihua Li1, Yadong Li1, Heng Zhang1, Chen Ding1, Jianbo Yang1, Haiwei Li1, Zhanlong He1, Longding Liu1, Guangnan Hu2, Shuying Liu3, Yanchun Che1, Shixia Wang2, Qihan Li1, Shan Lu2, Wei Cun1.   

Abstract

The current study aims to develop a safe and highly immunogenic COVID-19 vaccine. The novel combination of a DNA vaccine encoding the full-length Spike (S) protein of SARS-CoV-2 and a recombinant S1 protein vaccine induced high level neutralizing antibody and T cell immune responses in both small and large animal models. More significantly, the co-delivery of DNA and protein components at the same time elicited full protection against intratracheal challenge of SARS-CoV-2 viruses in immunized rhesus macaques. As both DNA and protein vaccines have been proven safe in previous human studies, and DNA vaccines are capable of eliciting germinal center B cell development, which is critical for high-affinity memory B cell responses, the DNA and protein co-delivery vaccine approach has great potential to serve as a safe and effective approach to develop COVID-19 vaccines that provide long-term protection.

Entities:  

Keywords:  DNA vaccine; SARS-CoV-2; non-human primate; protein vaccine; spike glycoprotein

Mesh:

Substances:

Year:  2021        PMID: 33555988      PMCID: PMC7928010          DOI: 10.1080/22221751.2021.1887767

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


  55 in total

1.  Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.

Authors:  Shixia Wang; Te-hui W Chou; Pavlo V Sakhatskyy; Song Huang; John M Lawrence; Hong Cao; Xiaoyun Huang; Shan Lu
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.

Authors:  Shixia Wang; Chris Parker; Jessica Taaffe; Alicia Solórzano; Adolfo García-Sastre; Shan Lu
Journal:  Vaccine       Date:  2008-05-19       Impact factor: 3.641

3.  The Covid-19 Vaccine-Development Multiverse.

Authors:  Penny M Heaton
Journal:  N Engl J Med       Date:  2020-07-14       Impact factor: 91.245

4.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Authors:  Pedro M Folegatti; Katie J Ewer; Parvinder K Aley; Brian Angus; Stephan Becker; Sandra Belij-Rammerstorfer; Duncan Bellamy; Sagida Bibi; Mustapha Bittaye; Elizabeth A Clutterbuck; Christina Dold; Saul N Faust; Adam Finn; Amy L Flaxman; Bassam Hallis; Paul Heath; Daniel Jenkin; Rajeka Lazarus; Rebecca Makinson; Angela M Minassian; Katrina M Pollock; Maheshi Ramasamy; Hannah Robinson; Matthew Snape; Richard Tarrant; Merryn Voysey; Catherine Green; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard
Journal:  Lancet       Date:  2020-07-20       Impact factor: 79.321

5.  DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.

Authors:  Julie E Ledgerwood; Chih-Jen Wei; Zonghui Hu; Ingelise J Gordon; Mary E Enama; Cynthia S Hendel; Patrick M McTamney; Melissa B Pearce; Hadi M Yassine; Jeffrey C Boyington; Robert Bailer; Terrence M Tumpey; Richard A Koup; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  Lancet Infect Dis       Date:  2011-10-03       Impact factor: 25.071

6.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

Authors:  Mark J Mulligan; Kirsten E Lyke; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; Kathleen Neuzil; Vanessa Raabe; Ruth Bailey; Kena A Swanson; Ping Li; Kenneth Koury; Warren Kalina; David Cooper; Camila Fontes-Garfias; Pei-Yong Shi; Özlem Türeci; Kristin R Tompkins; Edward E Walsh; Robert Frenck; Ann R Falsey; Philip R Dormitzer; William C Gruber; Uğur Şahin; Kathrin U Jansen
Journal:  Nature       Date:  2020-08-12       Impact factor: 69.504

Review 7.  DNA immunization as a technology platform for monoclonal antibody induction.

Authors:  Shuying Liu; Shixia Wang; Shan Lu
Journal:  Emerg Microbes Infect       Date:  2016-04-06       Impact factor: 7.163

8.  Development of an inactivated vaccine candidate for SARS-CoV-2.

Authors:  Qiang Gao; Linlin Bao; Haiyan Mao; Lin Wang; Kangwei Xu; Minnan Yang; Yajing Li; Ling Zhu; Nan Wang; Zhe Lv; Hong Gao; Xiaoqin Ge; Biao Kan; Yaling Hu; Jiangning Liu; Fang Cai; Deyu Jiang; Yanhui Yin; Chengfeng Qin; Jing Li; Xuejie Gong; Xiuyu Lou; Wen Shi; Dongdong Wu; Hengming Zhang; Lang Zhu; Wei Deng; Yurong Li; Jinxing Lu; Changgui Li; Xiangxi Wang; Weidong Yin; Yanjun Zhang; Chuan Qin
Journal:  Science       Date:  2020-05-06       Impact factor: 47.728

9.  Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.

Authors:  Noe B Mercado; Roland Zahn; Frank Wegmann; Carolin Loos; Abishek Chandrashekar; Jingyou Yu; Jinyan Liu; Lauren Peter; Katherine McMahan; Lisa H Tostanoski; Xuan He; David R Martinez; Lucy Rutten; Rinke Bos; Danielle van Manen; Jort Vellinga; Jerome Custers; Johannes P Langedijk; Ted Kwaks; Mark J G Bakkers; David Zuijdgeest; Sietske K Rosendahl Huber; Caroline Atyeo; Stephanie Fischinger; John S Burke; Jared Feldman; Blake M Hauser; Timothy M Caradonna; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Emily Hoffman; Catherine Jacob-Dolan; Marinela Kirilova; Zhenfeng Li; Zijin Lin; Shant H Mahrokhian; Lori F Maxfield; Felix Nampanya; Ramya Nityanandam; Joseph P Nkolola; Shivani Patel; John D Ventura; Kaylee Verrington; Huahua Wan; Laurent Pessaint; Alex Van Ry; Kelvin Blade; Amanda Strasbaugh; Mehtap Cabus; Renita Brown; Anthony Cook; Serge Zouantchangadou; Elyse Teow; Hanne Andersen; Mark G Lewis; Yongfei Cai; Bing Chen; Aaron G Schmidt; R Keith Reeves; Ralph S Baric; Douglas A Lauffenburger; Galit Alter; Paul Stoffels; Mathai Mammen; Johan Van Hoof; Hanneke Schuitemaker; Dan H Barouch
Journal:  Nature       Date:  2020-07-30       Impact factor: 49.962

10.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

Authors:  Denis Y Logunov; Inna V Dolzhikova; Olga V Zubkova; Amir I Tukhvatullin; Dmitry V Shcheblyakov; Alina S Dzharullaeva; Daria M Grousova; Alina S Erokhova; Anna V Kovyrshina; Andrei G Botikov; Fatima M Izhaeva; Olga Popova; Tatiana A Ozharovskaya; Ilias B Esmagambetov; Irina A Favorskaya; Denis I Zrelkin; Daria V Voronina; Dmitry N Shcherbinin; Alexander S Semikhin; Yana V Simakova; Elizaveta A Tokarskaya; Nadezhda L Lubenets; Daria A Egorova; Maksim M Shmarov; Natalia A Nikitenko; Lola F Morozova; Elena A Smolyarchuk; Evgeny V Kryukov; Vladimir F Babira; Sergei V Borisevich; Boris S Naroditsky; Alexander L Gintsburg
Journal:  Lancet       Date:  2020-09-04       Impact factor: 202.731

View more
  11 in total

1.  Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.

Authors:  Seyed Reza Banihashemi; Ali Es-Haghi; Mohammad Hossein Fallah Mehrabadi; Mojtaba Nofeli; Ali Rezaei Mokarram; Alireza Ranjbar; Mo Salman; Monireh Hajimoradi; Seyad Hossein Razaz; Maryam Taghdiri; Mohsen Bagheri; Maryam Dadar; Zuhair Mohammad Hassan; Mohammad Eslampanah; Zahra Salehi Najafabadi; Mohsen Lotfi; Akbar Khorasani; Fereidoon Rahmani
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

2.  Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques.

Authors:  Alexandra C Willcox; Kevin Sung; Meghan E Garrett; Jared G Galloway; Jesse H Erasmus; Jennifer K Logue; David W Hawman; Helen Y Chu; Kim J Hasenkrug; Deborah H Fuller; Frederick A Matsen Iv; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2022-04-11       Impact factor: 7.464

3.  Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2.

Authors:  Chen Huang; Yu Jiang; Jie Yan
Journal:  J Med Virol       Date:  2021-05-19       Impact factor: 20.693

4.  Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.

Authors:  Shengtao Fan; Kang Xiao; Dandan Li; Heng Zhao; Jingjing Zhang; Li Yu; Penglan Chang; Shuangli Zhu; Xingli Xu; Yun Liao; Tianjiao Ji; Guorun Jiang; Dongmei Yan; Fengyuan Zeng; Suqin Duan; Baicheng Xia; Lichun Wang; Fengmei Yang; Zhanlong He; Yang Song; Pingfang Cui; Xiaolei Li; Yaxing Zhang; Bangyi Zheng; Ying Zhang; Wenbo Xu; Qihan Li
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

5.  Macaque-human differences in SARS-CoV-2 Spike antibody response elicited by vaccination or infection.

Authors:  Alexandra C Willcox; Kevin Sung; Meghan E Garrett; Jared G Galloway; Megan A Oâ Connor; Jesse H Erasmus; Jennifer K Logue; David W Hawman; Helen Y Chu; Kim J Hasenkrug; Deborah H Fuller; Frederick A Matsen; Julie Overbaugh
Journal:  bioRxiv       Date:  2021-12-03

6.  Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.

Authors:  Margherita Rosati; Mahesh Agarwal; Xintao Hu; Santhi Devasundaram; Dimitris Stellas; Bhabadeb Chowdhury; Jenifer Bear; Robert Burns; Duncan Donohue; Laurent Pessaint; Hanne Andersen; Mark G Lewis; Evangelos Terpos; Meletios Athanasios Dimopoulos; Alexander Wlodawer; James I Mullins; David J Venzon; George N Pavlakis; Barbara K Felber
Journal:  PLoS Pathog       Date:  2021-09-22       Impact factor: 6.823

7.  Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.

Authors:  Ka-Wa Khong; Danlei Liu; Ka-Yi Leung; Lu Lu; Hoi-Yan Lam; Linlei Chen; Pui-Chun Chan; Ho-Ming Lam; Xiaochun Xie; Ruiqi Zhang; Yujing Fan; Kelvin Kai-Wang To; Honglin Chen; Kwok-Yung Yuen; Kwok-Hung Chan; Ivan Fan-Ngai Hung
Journal:  Vaccines (Basel)       Date:  2022-01-21

8.  Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice.

Authors:  Mariya B Borgoyakova; Larisa I Karpenko; Andrey P Rudometov; Ekaterina A Volosnikova; Iuliia A Merkuleva; Ekaterina V Starostina; Alexey M Zadorozhny; Anastasiya A Isaeva; Valentina S Nesmeyanova; Daniil V Shanshin; Konstantin O Baranov; Natalya V Volkova; Boris N Zaitsev; Lyubov A Orlova; Anna V Zaykovskaya; Oleg V Pyankov; Elena D Danilenko; Sergei I Bazhan; Dmitry N Shcherbakov; Alexander V Taranin; Alexander A Ilyichev
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

9.  Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates.

Authors:  Hui Zhao; Tie-Cheng Wang; Xiao-Feng Li; Na-Na Zhang; Liang Li; Chao Zhou; Yong-Qiang Deng; Tian-Shu Cao; Guan Yang; Rui-Ting Li; Yi-Jiao Huang; Yuan-Guo Li; Yi-Ming Zhang; Fang-Xu Li; Yu-Ren Zhou; Yu-Hang Jiang; Xi-Shan Lu; Shi-Hui Sun; Meng-Li Cheng; Kai-Ping Gu; Mei Zhang; Qing-Qing Ma; Xiao Yang; Bo Ying; Yu-Wei Gao; Cheng-Feng Qin
Journal:  Signal Transduct Target Ther       Date:  2021-12-24

10.  DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses.

Authors:  Haiying Li; Shixia Wang; Guangnan Hu; Lu Zhang; Shuying Liu; Shan Lu
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.